Asmanex Hfa

  • Asthma/COPD

Asmanex Hfa Generic Name & Formulations

General Description

Mometasone furoate 50mcg, 100mcg, 200mcg; per actuation; metered-dose inhaler with dose counter.

Pharmacological Class


How Supplied

Inhaler—13g (120 inh)


Generic Availability


Asmanex Hfa Indications


Maintenance treatment of asthma as prophylactic therapy.

Limitations of Use

Not for relief of acute bronchospasm.

Asmanex Hfa Dosage and Administration


≥12yrs: Currently not on inhaled corticosteroids: initially 2 inh of 100mcg twice daily (AM & PM). Currently receiving chronic oral corticosteroid therapy (eg, prednisone): initially 2 inh of 200mcg twice daily (AM & PM). If inadequate response after 2 weeks, may increase dose for additional control. Max: 800mcg/day (2 inh of 200mcg twice daily). Rinse mouth after use.


<5yrs: not established. 5–<12yrs: 2 inh of 50mcg twice daily (AM & PM). Max: 200mcg/day.

Asmanex Hfa Contraindications


Primary treatment of status asthmaticus or acute asthma attacks.

Asmanex Hfa Boxed Warnings

Not Applicable

Asmanex Hfa Warnings/Precautions


Maintain regular regimen. Prescribe a short-acting, inhaled β2-agonist for acute symptoms. Re-evaluate immediately if episodes of asthma not responsive to bronchodilators; may need oral corticosteroid therapy. Immunosuppressed. Untreated infections (eg, fungal, bacterial, viral, parasitic), TB, ocular herpes simplex. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. Transferring from systemic steroids: taper gradually. If adrenal insufficiency exists following systemic corticosteroids, replacement with inhaled steroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). May unmask previously suppressed allergic conditions. Monitor for bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, reduce gradually). Glaucoma, increased intraocular pressure, and cataracts: consider eye evaluation if ocular symptoms develop or in long term use. Severe hepatic impairment. Labor & delivery. Pregnancy. Nursing mothers: not recommended.

Asmanex Hfa Pharmacokinetics

See Literature

Asmanex Hfa Interactions


Potentiated by ketoconazole or other strong CYP3A4 inhibitors (eg, ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin); use caution and monitor.

Asmanex Hfa Adverse Reactions

Adverse Reactions

Nasopharyngitis, headache, sinusitis, bronchitis, influenza; oropharyngeal candidiasis, hypersensitivity reactions, paradoxical bronchospasm; discontinue if occurs.

Asmanex Hfa Clinical Trials

See Literature

Asmanex Hfa Note

Not Applicable

Asmanex Hfa Patient Counseling

See Literature